Patents Assigned to Eton Pharmaceuticals, Inc.
  • Hydrocortisone oral liquid formulations
    Patent number: 11904046
    Abstract: Provided herein are oral liquid formulations of hydrocortisone. Also provided herein are methods of making and using hydrocortisone oral liquid compositions for the treatment of certain diseases including endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, and others.
    Type: Grant
    Filed: February 23, 2023
    Date of Patent: February 20, 2024
    Assignee: ETON PHARMACEUTICALS, INC.
    Inventors: Danka Radosavljevic, Sean Brynjelsen, Romona Bhattacharya, Kalyan Kathala
  • More potent and less toxic formulations of epinephrine and methods of medical use
    Patent number: 11266611
    Abstract: The present invention provides pharmaceutical formulations of levorotatory-epinephrine, 1-epinephrine, more potent and less toxic than existing pharmaceutical formulations of epinephrine, along with methods of producing and using these pharmaceutical formulations of 1-epinephrine, including preventing and or treating hypotension and hemostasis under surgical anesthesia.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: March 8, 2022
    Assignee: ETON PHARMACEUTICALS, INC.
    Inventor: Darren Rubin
  • Pharmaceutical formulations of xanthine or xanthine derivatives, and their use
    Patent number: 9849133
    Abstract: The present invention relates to pharmaceutical formulations comprising xanthine or xanthine derivatives, kits thereof, and methods for treating fibrotic diseases by local administration.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: December 26, 2017
    Assignee: Eton Pharmaceuticals, Inc.
    Inventor: Matthew J. Buderer